Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367343 | 0.90 | EGFR (0.36) | EGFRERBB2LMNAMAPK1KDM4E | |
| SCHEMBL15607876 | 0.85 | ALDH1A1 (0.37) | EGFRERBB2LMNAMAPK1POLB | |
| SCHEMBL16367302 | 0.85 | POLB (0.36) | LMNAMAPK1POLBKDM4EMAPT | |
| SCHEMBL16367365 | 0.85 | MMP2 (0.36) | EGFRERBB2LMNAMAPK1POLB | |
| SCHEMBL15607811 | 0.85 | EGFR (0.36) | EGFRERBB2MAPK1POLBKDM4E | |
| SCHEMBL16367353 | 0.83 | EGFR (0.52) | EGFRERBB2LMNAMAPK1KDM4E | |
| SCHEMBL16367310 | 0.79 | POLB (0.37) | LMNAMAPK1POLBKDM4EMAPT | |
| SCHEMBL16367345 | 0.79 | L3MBTL1 (0.38) | EGFRERBB2LMNAMAPK1POLB | |
| SCHEMBL8423991 | 0.78 | STAT3 (0.44) | LMNAMAPK1KMT2AALDH1A1STAT3 | |
| SCHEMBL15544213 | 0.75 | PSMD10 (0.37) | EGFRERBB2PSMD10ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | EGFR 1866/4885ERBB2 1218/4885LMNA 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.